Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

BACKGROUND: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum...

Descripción completa

Detalles Bibliográficos
Autores principales: Llanos-Cuentas, Alejandro, Casapia, Martin, Chuquiyauri, Raúl, Hinojosa, Juan-Carlos, Kerr, Nicola, Rosario, Maria, Toovey, Stephen, Arch, Robert H, Phillips, Margaret A, Rozenberg, Felix D, Bath, Jade, Ng, Caroline L, Cowell, Annie N, Winzeler, Elizabeth A, Fidock, David A, Baker, Mark, Möhrle, Jörg J, Hooft van Huijsduijnen, Rob, Gobeau, Nathalie, Araeipour, Nada, Andenmatten, Nicole, Rückle, Thomas, Duparc, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060173/
https://www.ncbi.nlm.nih.gov/pubmed/29909069
http://dx.doi.org/10.1016/S1473-3099(18)30309-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060173/
https://www.ncbi.nlm.nih.gov/pubmed/29909069
http://dx.doi.org/10.1016/S1473-3099(18)30309-8

Ejemplares similares